comparemela.com
  1. Home
  2. Live Updates
  3. Momna Ali - Breaking News

Latest Breaking News On - Momna ali - Page 1 : comparemela.com

Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Robert wessmanMomna aliCameroni alvotechRheumatology informatics systemClinical disease activity indexDisease activityRheumatoid arthritisGlobenewswire news

Alvotech s AVT05 emerges as leading contender in rheumatoid arthritis market

The patent for Janssen’s second-generation, tumour necrosis factor-alpha (TNF)-a inhibitor Simponi (golimumab), is scheduled to expire in 2024 and in 2025 in the US and EU, respectively.

Advanz pharmaMomna aliRheumatoid arthritisGlobal drug forecastMarket analysisBio developmentsMarkets amp regulationsEmerging marketsRheumatoid arthritis

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.